Accurate Mammogram Reading More Likely Following Mammotome Biopsy, Study Indicates

News
Article
OncologyONCOLOGY Vol 12 No 7
Volume 12
Issue 7

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual

Mammotome biopsy causes significantly less internal breast scarring than open surgical biopsy and is less likely to interfere with a radiologist’s ability to read subsequent mammograms, according to a new study presented at the third annual Multidisciplinary Symposium on Breast Disease in Amelia Island, Florida, a medical conference of radiologists and surgeons specializing in breast disease.

The study indicates that, compared to Mammotome biopsy, internal scarring from open surgical breast biopsy is more than twice as likely to influence the radiologist’s ability to read a subsequent mammogram. Researchers also found that open surgical biopsy caused nearly twice as much internal scarring as did Mammotome biopsy.

Scarring and Mammography

The study suggests that women who have open surgical biopsy are more likely to develop changes on future mammograms than are women who have had a Mammotome biopsy, said lead author Catherine A. Kusnick, MD, assistant professor of radiology at the University of Iowa College of Medicine. These changes may require additional mammographic evaluation on future mammograms.

Scarring from open surgical biopsy influenced the confidence level in reading mammograms in more than 72% of cases studied. In contrast, Mammotome biopsy influenced the confidence level in only 29.5% of cases studied.

"This is a significant improvement. Post biopsy scarring can sometimes mimic or mask subtle breast cancers. The reduced rate of scarring from Mammotome biopsy compared to surgical biopsy may make it easier for radiologists to read future mammograms," said Dr. Kusnick.

Researchers identified scarring on one-half of mammograms following open surgical biopsy, as compared with only 27.3% of mammograms following Mammotome biopsy.

The study involved five radiologists specializing in mammography but with different experience levels, who were blinded to biopsy technique, breast lesion location, and identifying features. The radiologists examined two sets of mammograms, 14 surgical and 19 Mammotome cases. Even with the relatively small number of cases, the methodology and findings indicate significant statistical accuracy for the study, Dr. Kusnick said.

Minimally Invasive

Mammotome biopsy allows women to have a quick, minimally invasive breast biopsy. During the half-hour, outpatient procedure, the physician inserts a sampling probe through a small nick in the patient’s breast, which does not have to be repeatedly removed and inserted. Following the biopsy, the patient goes home with a small adhesive strip to cover the skin nick.

Open surgical biopsy, by comparison, is a more costly, time-consuming process that requires anesthesia, an operating room, and sutures.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Related Content